Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted to its projects, this time from the Government to apply work towards skin diseases and pancreatic cancer. The NMHRC Drug Development Grant scheme is an Australian government initiative set up to provide financial aid to
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.